May, 2024
May 2024
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Karen Knudsen: I’m pleased to share that the 2024 Fit2Be Cancer Free challenge is off to an incredible start!
Apr 21, 2024, 11:45

Karen Knudsen: I’m pleased to share that the 2024 Fit2Be Cancer Free challenge is off to an incredible start!

Karen Knudsen shared a post on LinkedIn:

“I’m pleased to share that the 2024 Fit2Be Cancer Free challenge is off to an incredible start! Our more than 18,800 participants have already racked up over 68,000 miles. Wow!

We also had 74 CEOs participate in yesterday’s one-day CEO step challenge. In total, the group accumulated an impressive 3,131,916 steps! Congratulations to our top three finishers:

  • Ethan Brown of Beyond Meat.
  • Juan Ignacio Diddi of Bristol Myers Squibb.
  • Craig Robinson of FlowPlay.

Special shout out to Ethan, who logged a record 189,914 steps, and our “Most Socially Active” award winner Steve O’Loughlin! And of course, congratulations to ACS’ own William Dahut who walked more than 73,000 steps. Remember there are still 20 days left in our employee challenge! You can support the challenge and check out the leaderboard here.”

Source: Karen Knudsen/LinkedIn

Karen E. Knudsen is the CEO of the American Cancer Society (ACS) and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN). Prior to joining ACS, Dr. Knudsen served as executive vice president of Oncology Services and enterprise director for Sidney Kimmel Cancer Center at Jefferson Health. She also served as president for the Association of American Cancer Institutes (AACI), representing the 102 leading cancer centers in North America, and on the board of directors of the American Association for Cancer Research (AACR). Dr. Knudsen currently holds leadership roles with some of the most important cancer entities in the United States. She serves on the board of advisors for the National Cancer Institute and on 12 external advisory boards for NCI-designated cancer centers. She is an active member of several committees with the American Society for Clinical Oncology (ASCO), in addition to serving on other academic and for-profit advisory boards.